MedTrace Logo

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

NCT04311671 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12979

Last updated 2026-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.

Conditions

  • Onchocerciasis

Interventions

DRUG

Moxidectin

2 mg tablets, encapsulated for blinding

DRUG

Ivermectin

3 mg tablets, encapsulated for blinding

DRUG

Albendazole

400 mg tablets

Sponsors & Collaborators

  • Medicines Development for Global Health

    lead OTHER

Principal Investigators

  • Tony Ukety, MD, DO, MPH · Centre de Recherche en Maladies Tropicales de l'Ituri

  • Benjamin Koudou, PhD · Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2024-09-27
Completion
2024-09-27
FDA Drug
Yes

Countries

  • Côte d’Ivoire
  • Democratic Republic of the Congo

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311671 on ClinicalTrials.gov